Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.87% | -19.46% | -27.36% | -34.43% | 28.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.35% | 93.04% | 49.97% | 17.37% | 34.36% |
| Operating Income | -71.35% | -93.04% | -49.97% | -17.37% | -34.36% |
| Income Before Tax | -70.30% | -92.62% | -51.31% | -18.72% | -36.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.53% | -95.54% | -51.31% | -18.72% | -36.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.53% | -95.54% | -51.31% | -18.72% | -36.00% |
| EBIT | -71.35% | -93.04% | -49.97% | -17.37% | -34.36% |
| EBITDA | -71.35% | -93.07% | -49.96% | -17.32% | -84.04% |
| EPS Basic | 66.98% | 71.46% | 75.75% | 60.89% | 43.05% |
| Normalized Basic EPS | 67.64% | 71.90% | 75.75% | 60.89% | 43.05% |
| EPS Diluted | 66.98% | 71.46% | 75.75% | 60.89% | 43.05% |
| Normalized Diluted EPS | 67.64% | 71.90% | 75.75% | 60.89% | 43.05% |
| Average Basic Shares Outstanding | 207.59% | 404.14% | 537.44% | 341.37% | 250.90% |
| Average Diluted Shares Outstanding | 207.59% | 404.14% | 537.44% | 341.37% | 250.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |